

# Diane Thiboutot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5909227/publications.pdf>

Version: 2024-02-01

47  
papers

2,966  
citations

257357

24  
h-index

233338

45  
g-index

48  
all docs

48  
docs citations

48  
times ranked

1881  
citing authors

#	ARTICLE	IF	CITATIONS
1	Isotretinoin Laboratory Monitoring in Acne Treatment. <i>JAMA Dermatology</i> , 2022, 158, 942.	2.0	12
2	Reviewing the global burden of acne: how could we improve care to reduce the burden?*. <i>British Journal of Dermatology</i> , 2021, 184, 219-225.	1.4	66
3	Identifying the Impacts of Acne and the Use of Questionnaires to Detect These Impacts: A Systematic Literature Review. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 159-171.	3.3	17
4	Developing a Core Outcome Set for Acne Clinical Trials: Towards Standardization and Harmonization. <i>Updates in Clinical Dermatology</i> , 2021, , 25-33.	0.1	0
5	What Matters the Most to Adult Women With Acne?. <i>JAMA Dermatology</i> , 2021, 157, 1035.	2.0	0
6	Gaps and recommendations for clinical management of truncal acne from the Personalising Acne: Consensus of Experts panel. <i>JAAD International</i> , 2021, 5, 33-40.	1.1	7
7	Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the Personalising Acne: Consensus of Experts panel. <i>JAAD International</i> , 2021, 5, 41-48.	1.1	6
8	The Personalised Acne Care Pathwayâ€™ Recommendations to guide longitudinal management from the Personalising Acne: Consensus of Experts. <i>JAAD International</i> , 2021, 5, 101-111.	1.1	8
9	Recommendations for rosacea diagnosis, classification and management: update from the global <scp>ROS</scp> acea <scp>CO</scp> nsensus 2019 panel. <i>British Journal of Dermatology</i> , 2020, 182, 1269-1276.	1.4	113
10	Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1501-1510.	0.6	89
11	Identifying the Impacts of Acne: A Delphi Survey of Patients and Clinicians. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 259-266.	0.6	7
12	Changes in the management of acne: 2009-2019. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1268-1269.	0.6	19
13	Selective Ah Receptor Ligands Mediate Enhanced SREBP1 Proteolysis to Restrict Lipogenesis in Sebocytes. <i>Toxicological Sciences</i> , 2019, 171, 146-158.	1.4	11
14	Assessing effectiveness in acne clinical trials: steps towards a core outcome measure set. <i>British Journal of Dermatology</i> , 2019, 181, 700-706.	1.4	10
15	Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. <i>British Journal of Dermatology</i> , 2018, 178, e279-e285.	1.4	29
16	Development of a Comprehensive Quality-of-Life Measure for Facial and Torso Acne. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 304-311.	0.6	19
17	Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 148-155.	0.6	295
18	Artificial Intelligence for the Objective Evaluation of Acne Investigator Global Assessment. <i>Journal of Drugs in Dermatology</i> , 2018, 17, 1006-1009.	0.4	17

#	ARTICLE	IF	CITATIONS
19	Development of an atrophic acne scar risk assessment tool. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1547-1554.	1.3	30
20	Identifying What to Measure in Acne Clinical Trials: First Steps towards Development of a Core Outcome Set. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1784-1786.	0.3	31
21	Rosacea treatment update: recommendations from the global <scp>ROS</scp> acea <scp>CO</scp> nsensus ( <scp>ROSCO</scp> ) panel. <i>British Journal of Dermatology</i> , 2017, 176, 465-471.	1.4	122
22	Hormonal therapies for acne. <i>Clinics in Dermatology</i> , 2017, 35, 168-172.	0.8	24
23	Updating the diagnosis, classification and assessment of rosacea: recommendations from the global <scp>ROS</scp> acea <scp>CO</scp> nsensus ( <scp>ROSCO</scp> ) panel. <i>British Journal of Dermatology</i> , 2017, 176, 431-438.	1.4	177
24	G2A Attenuates<i>Propionibacterium acnes</i> Induction of Inflammatory Cytokines in Human Monocytes. <i>Annals of Dermatology</i> , 2017, 29, 688.	0.3	6
25	Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic Prescribing Patterns, Sources of Antibiotic Exposure, Antibiotic Consumption and Emergence of Antibiotic Resistance, Impact of Alterations in Antibiotic Prescribing, and Clinical Sequelae of Antibiotic Use. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, 18-24.	0.1	14
26	Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 3: Current Perspectives on Skin and Soft Tissue Infections with Emphasis on Methicillin-resistant <i>Staphylococcus aureus</i> , Commonly Encountered Scenarios when Antibiotic Use May Not Be Needed, and Concluding Remarks on Rational Use of Antibiotics in Dermatology. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, 17-24.	0.1	9
27	Understanding innate immunity and inflammation in acne: implications for management. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 3-11.	1.3	116
28	Large-scale international study enhances understanding of an emerging acne population: adult females. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1096-1106.	1.3	101
29	Antibiotic stewardship in dermatology: limiting antibiotic use in acne. <i>European Journal of Dermatology</i> , 2014, 24, 330-334.	0.3	89
30	Acne severity grading: Determining essential clinical components and features using a Delphi consensus. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 187-193.	0.6	60
31	Dermatologists Do Not Yet Fully Understand the Clinical Significance of Antibiotic Use and Bacterial Resistance in Patients With Acne. <i>Archives of Dermatology</i> , 2011, 147, 921.	1.7	10
32	New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne Group. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, S1-S50.	0.6	657
33	A 3-step acne system containing solubilized benzoyl peroxide versus clindamycin-benzoyl peroxide. <i>Cutis</i> , 2009, 84, 48-55.	0.4	3
34	Standard management options for rosacea, part 2: options according to subtype. <i>Cutis</i> , 2009, 84, 97-104.	0.4	36
35	Versatility of azelaic acid 15% gel in treatment of inflammatory acne vulgaris. <i>Journal of Drugs in Dermatology</i> , 2008, 7, 13-6.	0.4	35
36	Acne counseling to improve adherence. <i>Cutis</i> , 2008, 81, 81-6.	0.4	27

#	ARTICLE	IF	CITATIONS
37	Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. <i>Journal of Drugs in Dermatology</i> , 2008, 7, s3-10.	0.4	19
38	Acne: Hormonal concepts and therapy. <i>Clinics in Dermatology</i> , 2004, 22, 419-428.	0.8	116
39	Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from two vehicle-controlled, randomized phase III studies. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, 836-845.	0.6	140
40	A randomized, parallel, vehicle-controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. <i>Clinical Therapeutics</i> , 2002, 24, 773-785.	1.1	17
41	Health-related quality of life among patients with facial acne - assessment of a new acne-specific questionnaire. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 380-385.	0.6	118
42	Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. <i>Cutis</i> , 2001, 68, 10-9.	0.4	24
43	New Treatments and Therapeutic Strategies for Acne. <i>Archives of Family Medicine</i> , 2000, 9, 179-187.	1.5	89
44	Activity of 5-Alpha-Reductase and 17-Beta-Hydroxysteroid Dehydrogenase in the Infrainfundibulum of Subjects with and without Acne vulgaris. <i>Dermatology</i> , 1998, 196, 38-42.	0.9	62
45	Activity of type 1 5 $\alpha$ -reductase is greater in the follicular infrainfundibulum compared with the epidermis. <i>British Journal of Dermatology</i> , 1997, 136, 166-171.	1.4	7
46	Hormonal Therapy for Acne. <i>Journal of Cutaneous Medicine and Surgery</i> , 1996, 1, S2-26-S2-29.	0.6	2
47	Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. <i>Quality of Life Research</i> , 1996, 5, 481-490.	1.5	100